Crossref
Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia
Cancer · 2024
DOI: 10.1002/cncr.35579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Drug Approval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antibodies, BispecificPrecursor B-Cell Lymphoblastic Leukemia-LymphomaDrug ApprovalHumansConsolidation ChemotherapyNeoplasm, ResidualUnited StatesUnited States Food and Drug Administration
Substanzen
blinatumomabAntibodies, Bispecific
Zitieren
APA
Nierengarten, M. B. (2024). Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia. Cancer. https://doi.org/10.1002/cncr.35579
Vancouver
Nierengarten MB. Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia. Cancer. 2024. doi:10.1002/cncr.35579
BibTeX
@article{Nierengarten2024,
author = {Nierengarten, Mary Beth},
title = {Blinatumomab approved as consolidation therapy for MRD‐negative B‐cell precursor acute lymphoblastic leukemia},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35579}
}
EUVIMED